Still Uncertain About Sodium–Glucose Cotransporter Inhibitors Despite 2 Centuries of Study
Authors: Steven A. Smith
Journal: Annals of Internal Medicine (2012)

Editorials20 March 2012Still Uncertain About Sodium–Glucose Cotransporter Inhibitors Despite 2 Centuries of StudySteven A. Smith, MDSteven A. Smith, MDFrom Mayo College of Medicine, Rochester, MN 55905.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-6-201203200-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Dapagliflozin, the first in the class of selective renal sodium–glucose cotransporter (SGLT) inhibitors (1), offers a novel, insulin-independent mechanism of action for diabetes treatment. Nonselective SGLT inhibitors block adenosine triphosphate–dependent, sodium-linked facilitated transport of glucose across the brush border cells of the small intestine (isoform SGLT1) and renal tubular epithelium (dominantly isoform SGLT2), leading to decreased intestinal absorption and renal tubular resorption of glucose (2). Although SGLT inhibitors may represent a new class of drugs for managing hyperglycemia and possibly obesity, the understanding of the SGLT system, cellular glucose transport, and the ability to induce glycosuria as a potential management ...References1. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51:1145-9. [PMID: 18260618] CrossrefMedlineGoogle Scholar2. Lee YJ, Park SH, Han HJ. ATP stimulates Na+-glucose cotransporter activity via cAMP and p38 MAPK in renal proximal tubule cells. Am J Physiol Cell Physiol. 2005;289:C1268-76. [PMID: 16014705] CrossrefMedlineGoogle Scholar3. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31-8. [PMID: 15624123] CrossrefMedlineGoogle Scholar4. White JR. Apple trees to sodium glucose co-transporter ihibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28:5-10. CrossrefGoogle Scholar5. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32-43. [PMID: 17222166] CrossrefMedlineGoogle Scholar6. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. A randomized trial. Ann Intern Med. 2012;156:405-15. LinkGoogle Scholar7. U.S. Food and Drug Administration. FDA Advisory Committee Meeting: Dapagliflozin. Silver Spring, MD: U.S. Food and Drug Administration; 2011. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM264312.pdf on 10 February 2012. Google Scholar8. Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;69:852-5. [PMID: 16518345] CrossrefMedlineGoogle Scholar9. Magen D, Sprecher E, Zelikovic I, Skorecki K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int. 2005;67:34-41. [PMID: 15610225] CrossrefMedlineGoogle Scholar10. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14:2873-82. [PMID: 14569097] CrossrefMedlineGoogle Scholar11. Stanton RC. Comment on: Ferrannini. Learning from glycosuria. Diabetes 2011;60:695-696 [Letter]. Diabetes. 2011;60:e19; author reply e20. [PMID: 21709275] Google Scholar12. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002;111:544-7. [PMID: 12436245] CrossrefMedlineGoogle Scholar13. Brooks AM, Thacker SM. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2009;43:1286-93. [PMID: 19584379] CrossrefMedlineGoogle Scholar14. Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001;92:874-9. [PMID: 11509120] CrossrefMedlineGoogle Scholar15. Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, et al. The Sweet Pee model for SGLT2 mutation. J Am Soc Nephrol. 2011;22:113-23. [PMID: 21209254] CrossrefMedlineGoogle Scholar16. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578-86. [PMID: 11159708] CrossrefMedlineGoogle Scholar17. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427-34. [PMID: 16306358] CrossrefMedlineGoogle Scholar18. Ferrannini E. Learning from glycosuria. Diabetes. 2011;60:695-6. [PMID: 21357469] CrossrefMedlineGoogle Scholar19. Lang F. Risks and benefits of Sweet Pee [Editorial]. J Am Soc Nephrol. 2011;22:2-5. [PMID: 21164030] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Steven A. Smith, MDAffiliations: From Mayo College of Medicine, Rochester, MN 55905.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0217.Corresponding Author: Steven A. Smith, MD, Mayo College of Medicine, 200 First Street SE, Rochester, MN 55905; e-mail, smith.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLong-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin John P.H. Wilding , Vincent Woo , Norman G. Soler , Andrea Pahor , Jennifer Sugg , Katja Rohwedder , and Shamik Parikh , for the Dapagliflozin 006 Study Group* Metrics Cited byEmerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes 20 March 2012Volume 156, Issue 6Page: 466-467KeywordsBreast cancerClinical trial reportingClinical trialsDrugsFood and Drug AdministrationGenitourinary infectionsGlucoseInsulinSafetySurveillance Epidemiology and End Results ePublished: 20 March 2012 Issue Published: 20 March 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...